Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Short Interest Update

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 2,310,000 shares, a growth of 22.9% from the January 31st total of 1,880,000 shares. Approximately 9.2% of the company's shares are short sold. Based on an average daily volume of 256,500 shares, the short-interest ratio is presently 9.0 days.

Lexeo Therapeutics Stock Performance

NASDAQ LXEO traded down $0.11 during mid-day trading on Friday, reaching $2.70. 294,177 shares of the stock were exchanged, compared to its average volume of 355,843. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. The company has a market capitalization of $89.28 million, a P/E ratio of -0.85 and a beta of 3.86. Lexeo Therapeutics has a 1 year low of $2.32 and a 1 year high of $19.50. The business's 50 day moving average is $4.98 and its 200-day moving average is $7.37.

Hedge Funds Weigh In On Lexeo Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp lifted its holdings in Lexeo Therapeutics by 5.6% during the fourth quarter. Bank of New York Mellon Corp now owns 50,660 shares of the company's stock valued at $333,000 after purchasing an additional 2,677 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Lexeo Therapeutics by 30.1% during the fourth quarter. JPMorgan Chase & Co. now owns 13,371 shares of the company's stock valued at $88,000 after purchasing an additional 3,093 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in Lexeo Therapeutics by 184.2% during the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company's stock valued at $50,000 after purchasing an additional 3,591 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Lexeo Therapeutics by 49.9% during the fourth quarter. Wells Fargo & Company MN now owns 11,156 shares of the company's stock valued at $73,000 after purchasing an additional 3,714 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in Lexeo Therapeutics by 19.6% during the fourth quarter. Rhumbline Advisers now owns 25,197 shares of the company's stock valued at $166,000 after purchasing an additional 4,127 shares in the last quarter. 60.67% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on LXEO shares. Chardan Capital upped their price target on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Royal Bank of Canada restated an "outperform" rating and set a $24.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday, January 21st. HC Wainwright upped their price target on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the company a "buy" rating in a research note on Thursday, November 14th. Finally, Leerink Partners cut their price objective on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an "outperform" rating on the stock in a research note on Wednesday, November 13th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $23.80.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.